Location History:
- Nagoya, JP (2008 - 2018)
- Aichi, JP (2006 - 2020)
Company Filing History:
3 out of 949 
2 out of 272 
2 out of 371 
Years Active: 2006-2020
Title: Innovations of Tomoki Naoe in Cancer Treatment
Introduction
Tomoki Naoe is a prominent inventor based in Aichi, Japan, known for his significant contributions to the field of cancer treatment. With a total of nine patents to his name, Naoe has focused on developing methods and pharmaceutical compositions aimed at diagnosing and treating malignant lymphoma and leukemia.
Latest Patents
Among his latest patents, Naoe has developed a method for determining the presence or absence of suffering from malignant lymphoma or leukemia. This invention provides a detection step that identifies at least one of a fusion mutation of a DUX4 gene, an overexpression of a DUX4 gene, and a fusion mutation of an MEF2D gene. The determination step concludes whether a subject suffers from or is likely to suffer from the disease based on the detection results. Additionally, he has created a pharmaceutical composition that includes a DUX4 inhibitor as an active ingredient for treating and preventing malignant lymphoma or leukemia. Another notable patent involves a pharmaceutical composition for treating FLT3 mutation-positive cancer, which includes a mutant FLT3 inhibitor and methods for predicting therapeutic effects based on the presence of FLT3 mutations.
Career Highlights
Throughout his career, Tomoki Naoe has worked with notable companies such as Chugai Seiyaku Kabushiki Kaisha and Kyowa Hakko Kirin Co., Limited. His work in these organizations has contributed to advancements in cancer research and treatment methodologies.
Collaborations
Naoe has collaborated with esteemed colleagues in the field, including Hitoshi Kiyoi and Hiroshi Umehara. Their joint efforts have furthered the development of innovative solutions for cancer treatment.
Conclusion
Tomoki Naoe's innovative work in cancer treatment showcases his dedication to improving patient outcomes through advanced medical technologies. His patents reflect a commitment to addressing critical health challenges, particularly in the realm of hematological malignancies.